generating neoantigen-specific car t-cell therapies for multiple myeloma
Published 2 years ago • 121 plays • Length 5:48Download video MP4
Download video MP3
Similar videos
-
2:49
novel strategies to optimize car-t therapy in myeloma
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
2:20
novel car-t products in the pipeline for multiple myeloma
-
2:05
novel car-t constructs being explored in myeloma: t-charge platform
-
1:55
developing the next generation of car-t cells
-
5:10
what is multiple myeloma? - animated
-
11:03
behind the science - sequencing the single cancer cell
-
11:17
car-t cells: engineered cancer killers
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
4:20
utilizing neoantigen-specific tcrs for personalized immunotherapies
-
2:06
the optimal sequencing of car-t and other immunotherapies in multiple myeloma
-
2:30
an update on the current status of car-t therapy in multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:45
evaluating nivolumab-based therapy to restore t-cell fitness in patients with r/r multiple myeloma
-
2:19
novel avenues for mm treatment: car t-cells, venetoclax, induction & mrd
-
3:05
the development of inkt-car t-cells for hematological malignancies
-
1:53
phase i trial evaluating a gamma secretase inhibitor in combination with car-t cells in r/r myeloma
-
2:01
cellular therapy: nk-cells as a model
-
1:19
gene editing of nkg2a to enhance nk cell cytotoxicity against multiple myeloma cells
-
1:02
the use of car-t cell products in a real-world setting
-
1:44
developing autologous t-cell therapies with crispr-cas technology
-
1:12
an update in cellular therapies: gene editing for scd and immunotherapies for mm